Key Highlights

• Cogstate executed US$25.1 million in net sales contracts during the September 2026 quarter, up from US$21.42 million in the prior corresponding period

• The company secured five Phase 3 trials in bipolar and depression across two customers, contributing over 80% of the quarter's total contract value

• Contracted FY27 Revenue increased to US$56.8 million at 30 September 2026, up from US$48.3 million at the end of June 2026

Cogstate Ltd (ASX:CGS) closed at A$3.38 on 05 November 2026, adding 0.90% on the day. The broader S&P/ASX 200 index (XJO) gained 2.61%, or 230.60 points, to settle at 9,065.10, while the S&P/ASX 200 Health Care index (XHJ) advanced 3.64%, or 1,240.30 points, to 35,329.10. Overnight Wall Street gains, following the Democrats' decisive victory in the U.S. midterm elections, provided a tailwind for global Equity markets. Cogstate is a global Central Nervous System (CNS) endpoint innovations company that partners with pharmaceutical and biotech firms to power complex neuroscience clinical studies.

Quarterly Sales Contracts Reflect Growing Momentum

On 12 October 2026, Cogstate released its 1Q27 Business update for the quarter ended 30 September 2026, reporting net sales contracts executed during the period totalling US$25.1 million. This compares to US$21.42 million in the September quarter of FY26 and US$11.40 million in the same period of FY25, representing a year-over-year increase of approximately 17%.

The quarterly result was primarily driven by a competitive win of five Phase 3 trials in either bipolar or depression, across two customers. These trials contributed over 80% of the total contract sales value executed during the quarter. Cogstate noted that sponsors commonly retain providers from earlier development phases when progressing to Phase 3 studies, and the company's channel Partnership strategy was an important Factor in securing these programs.

Contracted Revenue Position and Revenue Recognition

Contracted FY27 revenue increased to US$56.8 million at 30 September 2026, compared to US$48.3 million at 30 June 2026. The US$25.1 million in new contracts contributed US$8.4 million to contracted FY27 revenue, representing an in-year revenue Yield of 34%. Cogstate noted that this yield was lower than typically expected for first-quarter sales, reflecting a lower-than-usual licence fee contribution of 7%, compared to a historical average of 20% to 25%, and the significant proportion of longer-duration Phase 3 trials.

The resulting revenue profile did, however, provide coverage for FY28, with contracted revenue for that period increasing to US$39.7 million from US$31.4 million at the end of June 2026. Total contracted revenue across all periods stood at US$143.7 million, up 41% from the prior corresponding period's US$101.8 million.

About Cogstate

Cogstate specialises in the science and service of CNS measurement, ensuring clinical trial endpoint data is accurate and actionable. The company's applied technology solutions include data quality programs, advanced analytics, and digital cognitive testing. In the Healthcare market, Cogstate provides primary care physicians and consumers with brief, scientifically validated digital measures of cognition. The company has built its offerings upon more than 25 years of customised collaborations with drug developers across the globe.

Sector Context

The ASX-listed healthcare sector enjoyed broad-based gains on 05 November 2026, with the Health Care sub-index rising 3.64%. The rally was underpinned by positive sentiment flowing from overnight U.S. markets, as well as continued investor interest in clinical-stage and diagnostics companies. Within the CNS trial services space, Demand for endpoint quality and digital assessment tools has been increasing as drug developers pursue complex neuroscience studies involving conditions such as Alzheimer's disease, depression, and bipolar disorder.

Risks

Cogstate's revenue recognition is inherently lumpy, given its dependence on the timing of contract execution and the pace of clinical trial enrolment, which is outside the company's control. The lower licence fee contribution observed in 1Q27 highlights the variability in revenue yield from quarter to quarter. Additionally, competitive dynamics in the clinical trial services market could affect the company's ability to sustain Market Share gains. Currency movements between the U.S. dollar and Australian dollar also present a translation risk for reported results.

Catalysts on Watch

Investors may be watching for continued execution of the channel partnership strategy, which has enabled Cogstate to win work in competitive situations. The progression of contracted revenue into FY28 and beyond provides forward visibility, while any additional Phase 3 trial wins could further expand the revenue backlog. The growth of the Healthcare division, including digital cognitive testing for primary care, represents another potential avenue for revenue diversification.

The Road Ahead

Cogstate's 1Q27 update reflects continued momentum in securing clinical trial contracts, particularly in mood disorder studies. The channel partnership model appears to be broadening the company's reach, while the contracted revenue base provides forward visibility into FY27 and FY28. The company's Annual General Meeting was scheduled for 15 October 2026 in Melbourne.